Search results
Results from the WOW.Com Content Network
As of 2019, twelve of top 20 biopharmaceutical companies in the world has U.S. headquarters in the state. [9] [10] Below is a list of notable New York metropolitan area biotechnology and pharmaceutical corporations, including companies with either global or U.S. headquarters in the metropolitan region encompassing and surrounding New York City.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, [2] especially in relation to approaches making use of new cell therapy or gene therapy developments. [3]
Shares of small biotech firm Enzon were up about 5% today after the CEO announced that Lazard had been hired to look into potentially selling some or all of the company. Carl Icahn, who has a 13% ...
For premium support please call: 800-290-4726 more ways to reach us
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
These top new emerging technologies not only power digital transformation in business, but set the stage for other solutions, including the metaverse, cryptocurrencies, biotechnology, and many others.
In April 2020, the company began human Phase I safety studies of its lead vaccine (INO-4800) in the United States, and a Phase I-II trial in South Korea, to test for immunization against the COVID-19 virus. [4] [24] In April 2021, the US Department of Defense discontinued funding of future phase III trials of INO-4800. [25]